Castle Biosciences will present at the Stephens Investment Conference and participate in the Jefferies Healthcare Conference in November 2025.
Quiver AI Summary
Castle Biosciences, Inc. announced that its executive management will present a company overview at the Stephens 27th Annual Investment Conference on November 19, 2025, at 10:00 a.m. Eastern time, with a live audio webcast available on its website. Additionally, the company will engage in one-on-one investor meetings during the Jefferies Global Healthcare Conference taking place from November 18-20, 2025. Castle Biosciences specializes in innovative diagnostic tests aimed at guiding patient care, particularly for skin cancers, Barrett’s esophagus, and uveal melanoma, while also pursuing research for treatments related to other high-need diseases.
Potential Positives
- Castle Biosciences is scheduled to present at the Stephens 27th Annual Investment Conference, which may enhance visibility and attract potential investors.
- The company has ongoing research and development programs for tests in high clinical need, highlighting its commitment to innovation and potential future growth.
- Castle Biosciences is actively participating in the Jefferies Global Healthcare Conference, allowing for direct engagement with investors, which could strengthen investor relations.
Potential Negatives
- The press release does not provide any financial updates or performance metrics, which may raise concerns among investors about the company's current financial health and market position.
- The reliance on upcoming investor conferences for engagement may indicate a lack of proactive communication or ongoing transparency from the company, potentially leading to investor dissatisfaction.
- No mention is made of recent achievements or milestones achieved by the company, which could create an impression of stagnation or lack of progress in its strategic initiatives.
FAQ
When is Castle Biosciences presenting at the Stephens Conference?
Castle Biosciences will present on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time.
How can I access the live webcast of Castle's presentation?
The live audio webcast can be accessed via Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/.
Will there be a replay of the presentation available?
Yes, a replay of the webcast will be available after the live broadcast concludes.
What other conferences is Castle Biosciences attending?
Castle will be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, from Nov. 18-20, 2025.
What is Castle Biosciences known for?
Castle Biosciences specializes in innovative tests for diseases like skin cancers and Barrett’s esophagus, guiding patient care.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CSTL Insider Trading Activity
$CSTL insiders have traded $CSTL stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 13 sales selling 72,290 shares for an estimated $1,445,912.
- KRISTEN M OELSCHLAGER (Chief Operating Officer) has made 0 purchases and 2 sales selling 30,684 shares for an estimated $669,706.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CSTL Hedge Fund Activity
We have seen 88 institutional investors add shares of $CSTL stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 630,133 shares (+243.9%) to their portfolio in Q2 2025, for an estimated $12,867,315
- PARK WEST ASSET MANAGEMENT LLC removed 556,485 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,363,423
- BRAIDWELL LP added 457,488 shares (+125.3%) to their portfolio in Q2 2025, for an estimated $9,341,904
- WELLINGTON MANAGEMENT GROUP LLP removed 421,317 shares (-50.9%) from their portfolio in Q2 2025, for an estimated $8,603,293
- NUVEEN, LLC added 401,296 shares (+59.7%) to their portfolio in Q2 2025, for an estimated $8,194,464
- PRINCIPAL FINANCIAL GROUP INC added 331,101 shares (+22.6%) to their portfolio in Q2 2025, for an estimated $6,761,082
- UBS GROUP AG added 315,089 shares (+646.2%) to their portfolio in Q2 2025, for an estimated $6,434,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/09/2025
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Lake Street issued a "Buy" rating on 05/06/2025
To track analyst ratings and price targets for $CSTL, check out Quiver Quantitative's $CSTL forecast page.
$CSTL Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 3 analysts offer price targets for $CSTL in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $37.0 on 09/09/2025
- Sung Ji Nam from Scotiabank set a target price of $40.0 on 05/21/2025
- Thomas Flaten from Lake Street set a target price of $35.0 on 05/06/2025
Full Release
FRIENDSWOOD, Texas, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens 27 th Annual Investment Conference on Wednesday, Nov. 19, 2025, at 10:00 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/ . A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Jefferies Global Healthcare Conference, being held Nov. 18-20, 2025. Meetings may be requested exclusively through Jefferies Financial Group.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide treatment decisions for patients with moderate-to-severe atopic dermatitis. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
[email protected]
Media Contact:
Allison Marshall
[email protected]
Source: Castle Biosciences Inc.
